Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$0.43
-10.2%
$0.42
$0.30
$3.33
$10.10M-1.381.65 million shs843,288 shs
Ainos, Inc. stock logo
AIMD
Ainos
$0.50
+3.7%
$0.55
$0.40
$1.07
$10.48M2.2245,292 shs258,441 shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$2.90
-4.3%
$3.14
$2.51
$4.86
$8.82M-0.68134,533 shs31,672 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$0.00
$710K-0.2144,492 shs5,000 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
0.00%-21.82%+12.48%+10.26%-80.89%
Ainos, Inc. stock logo
AIMD
Ainos
0.00%-1.07%-25.90%+1.79%-38.54%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
0.00%-9.38%-4.61%-3.65%-30.95%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%0.00%-50.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
2.7765 of 5 stars
3.53.00.00.03.81.70.0
Ainos, Inc. stock logo
AIMD
Ainos
0.919 of 5 stars
0.04.00.00.01.41.70.6
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
2.6834 of 5 stars
3.52.00.00.03.31.70.6
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
3.00
Buy$8.001,760.47% Upside
Ainos, Inc. stock logo
AIMD
Ainos
0.00
N/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
3.00
Buy$10.00244.83% Upside
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NPHC, AIMD, KPRX, and ACXP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$8.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/A$0.03 per shareN/A
Ainos, Inc. stock logo
AIMD
Ainos
$20K524.00N/AN/A$1.10 per share0.45
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$16.02M0.55$1.24 per share2.34$8.58 per share0.34
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$14.10M-$0.70N/AN/AN/AN/A-526.78%-223.78%8/8/2025 (Estimated)
Ainos, Inc. stock logo
AIMD
Ainos
-$14.86M-$1.29N/AN/AN/A-88.07%-48.60%8/4/2025 (Estimated)
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$3.60M-$2.90N/AN/AN/AN/A-42.82%-32.18%8/8/2025 (Estimated)
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/A0.00N/AN/AN/AN/AN/A

Latest NPHC, AIMD, KPRX, and ACXP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.14-$0.11+$0.03-$0.11N/AN/A
5/12/2025Q1 2025
Ainos, Inc. stock logo
AIMD
Ainos
N/A-$0.21N/A-$0.21N/A$0.11 million
5/9/2025Q1 2025
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/AN/A
Ainos, Inc. stock logo
AIMD
Ainos
N/AN/AN/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/A
1.93
1.93
Ainos, Inc. stock logo
AIMD
Ainos
0.84
2.00
1.91
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/A
5.14
5.14
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
11.53%
Ainos, Inc. stock logo
AIMD
Ainos
N/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
76.97%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A

Insider Ownership

CompanyInsider Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
26.00%
Ainos, Inc. stock logo
AIMD
Ainos
10.39%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
0.05%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
323.48 million17.38 millionOptionable
Ainos, Inc. stock logo
AIMD
Ainos
4020.96 million18.78 millionNot Optionable
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
103.04 million3.04 millionNot Optionable
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable

Recent News About These Companies

Nutra Pharma Corp (NPHC)
Nutra Pharma Corp. Reaches Settlement with SEC
Nutra Pharma Corp. Reaches Settlement with SEC
Collegium Pharmaceutical
FAO report says over-fishing putting sea cucumbers at risk
Nutra Pharma Corp.
Nutri Pharmaceuticals Research Inc.
The best nutri-boost supplements for your pup
Nutra Pharma Corp. price
Active Health Foods (AHFD)
Medixall Group Inc (MDXL)
PharmaNutra buys Akern
Nutra Pharma signs first manufacturing agreement
Nutra Pharma Announces First Manufacturing Agreement

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acurx Pharmaceuticals stock logo

Acurx Pharmaceuticals NASDAQ:ACXP

$0.43 -0.05 (-10.25%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$0.44 +0.02 (+3.49%)
As of 06/27/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Ainos stock logo

Ainos NASDAQ:AIMD

$0.50 +0.02 (+3.69%)
As of 06/27/2025 04:00 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Kiora Pharmaceuticals stock logo

Kiora Pharmaceuticals NASDAQ:KPRX

$2.90 -0.13 (-4.29%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$2.96 +0.06 (+1.93%)
As of 06/27/2025 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

$0.0001 0.00 (0.00%)
As of 06/27/2025 10:45 AM Eastern

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.